CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
tolterodine tartrate +1 moredrug
Likely dose
tolterodine tartrate 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00768521
NCT00768521Phase 1Completed
CompareCT.gov

A Randomized, Placebo Controlled, Crossover Study to Evaluate the Effects of Tolterodine Tartrate on Urodynamic Parameters in Patients With Overactive Bladder

Merck Sharp & Dohme LLC·interventional·Posted Oct 8, 2008·Updated Feb 22, 2018

In Brief

A Phase 1 clinical trial evaluating tolterodine tartrate and Comparator: Placebo to tolterodine tartrate for Overactive Bladder. Completed, enrolled 20 participants.

Detailed Summary

This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 8, 2008
Enrollment StartSep 3, 2008
Primary CompletionJan 19, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.7 years ago

Interventions

tolterodine tartratedrug

Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days Part IIb: single dose tolterodine tartrate 4 mg capsule

Comparator: Placebo to tolterodine tartratedrug

Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule